GlassScriptPhysician profile
Dennis J Meisner
NPI 1730150434
$1,777.27
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $1,026 · 2021: $50.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,001.33 | 2019-2020 | |
| Incyte Corporation | $131.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.50 | 2019 | |
| Amgen INC. | $82.90 | 2019-2021 | |
| Pfizer INC. | $59.75 | 2019 | |
| Astellas Pharma US INC | $47.93 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $47.63 | 2019 | |
| Genentech USA, INC. | $44.77 | 2019 | |
| Clovis Oncology, INC. | $40.33 | 2019 | |
| Celgene Corporation | $36.33 | 2019-2020 | |
| Foundation Medicine, INC. | $28.18 | 2020-2021 | |
| Eisai INC. | $25.86 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.70 | 2019 | |
| Seagen INC. | $19.35 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.95 | 2020 | |
| Merck Sharp & Dohme LLC | $12.94 | 2020 | |
| Tesaro, INC. | $12.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Meisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.